New imaging tracer aims to peek at immune response in cancer patients
NCT ID NCT04260256
First seen Apr 08, 2026 · Last updated May 26, 2026 · Updated 9 times
Summary
This study tested a special PET imaging tracer to see if it could track immune cell activity in tumors after immunotherapy. Nine adults with advanced solid tumors received scans before and after starting checkpoint inhibitor therapy. The goal was to see if changes in the tracer signal matched immune cell levels in tumor biopsies and could predict treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORRELATE TRACER UPTAKE TO TCELL TUMOR INFILTRATION & CKIT BENEFIT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.